Tags: Drug.

Baricitinib (formerly INCB28050 LY3009104) is an oral JAK1 and JAK2 inhibitor. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy.The related compound in JAK inhibitor is Tofacitinib currently approved for the treatment of rheumatoid arthritis (RA) in the United States.

Baricitinib.svg
ATC prefix
None
CAS number
1187594-09-7
IUPAC name
2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[23-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
PubChem
44205240

Loading...

This page contains content from the copyrighted Wikipedia article "Baricitinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.